EcoDrugPlus

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSSMAG00000007934
Gene Symbol: NTRK2B
3 Cross references
207 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSSMAG00000000077
Gene Symbol: NAMPT
3 Cross references
225 Possible Orthologues:

Notch Receptor 1a

Ensembl ID : ENSSMAG00000008857
Gene Symbol: NOTCH1A
2 Cross references
196 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSSMAG00000010263
Gene Symbol: NOTCH1B
1 Cross references
201 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSSMAG00000003624
Gene Symbol: NOTCH3
1 Cross references
197 Possible Orthologues:

Nuclear Factor, Erythroid 2-Like 2a

Ensembl ID : ENSSMAG00000015270
Gene Symbol: NFE2L2A
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSSMAG00000009312
Gene Symbol: NR1H3
1 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSSMAG00000007024
Gene Symbol: NR1H4
3 Cross references
386 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSSMAG00000004511
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSSMAG00000004972
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSSMAG00000004328
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSSMAG00000009305
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).